2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phospholipase
  5. Phospholipase C Isoform

Phospholipase C

 

Phospholipase C Related Products (7):

Cat. No. Product Name Effect Purity
  • HY-P2817
    Phospholipase C
    Phospholipase C (PLCs) is a class of phospholipases. Phospholipase C participates in cellular signaling and regulation by virtue of its ability to hydrolyze membrane phospholipids into di-acyl-glycerol (DAG) and inositol triphosphate (IP3), which further causes the activation of other signaling pathways involved in various processes, including immune response.
  • HY-P2139
    Ranakinin
    		Activator
    Ranakinin is a NK1R agonist. Ranakinin inhibits the binding of selective NK1 radioligands to NK1 receptors. Ranakinin activates phospholipase C (Phospholipase C), thereby enhancing polyphosphoinositide hydrolysis. Ranakinin stimulates inositol phosphate production and reduces membrane polyphosphoinositide levels. Ranakinin stimulates corticosterone and aldosterone secretion.
  • HY-177218
    M119
    		Inhibitor
    M119 (NSC 119910) is a selective Gβγ-subunit inhibitor. M119 selectively potentiates μ-opioid-dependent antinociception. M119 inhibits μ-receptor-dependent phospholipase (PLC) activation. M119 can enhance opioid analgesia and attenuate its acute tolerance and dependence in mice. M119 can be used for pain research.
  • HY-162613
    ASM-IN-2
    		Inhibitor
    ASM-IN-2 (Compound 46) is a potent ASM inhibitor with an IC50 value of 0.87 μM, displaying good drug-like properties. ASM-IN-2 involves in multiple antidepressant mechanisms of actionin, which are associated with a decline of ceramide. It demostrates remarkable antidepressant effects in the CUMS-induced mouse, which is promising for research in the field of antidepressant drugs.
  • HY-182452
    U 84569
    		Inhibitor
    U 84569 is a potent low-Km cAMP-dependent Phosphodiesterase inhibitor, with an IC50 value of 300 nM in platelet cytosol. By inhibiting phosphodiesterase and elevating cAMP levels, U 84569 indirectly blocks receptor-mediated Phospholipase C activation, thereby inhibiting platelet aggregation.
  • HY-186140
    SHP1-IN-2
    		Activator
    SHP1‑IN‑2 is a selective and orally active SHP1 inhibitor. SHP1‑IN‑2 covalently binds to Cys480 of SHP1. SHP1‑IN‑2 elicits potent antitumor immunity and suppresses syngeneic tumor growth. SHP1‑IN‑2 blocks tumor progression in a svngeneic cancer model by activating natural killer cells and cytotoxic CD8＋ T cells, along with reduced T cel l. SHP1‑IN‑2 can be used for cancer‑related research.
  • HY-W778574
    BAPTA tetracesium
    		Inhibitor
    BAPTA tetracesium is a selective and cell-impermeant chelator for calcium. BAPTA tetracesium has high selectivity against magnesium and calcium. BAPTA tetracesium can also inhibit phospholipase C activity independently of their role as Ca2+ chelators.